SW
CRSP icon

SteelPeak Wealth’s CRISPR Therapeutics CRSP Stock Holding History

SteelPeak Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
6,314
-14,165
-69% -$747K 0.01% 497
2026
Q1 		$974K Buy
20,479
+8,447
+70% +$446K 0.03% 289
2025
Q4 		$631K Buy
12,032
+3,095
+35% +$185K 0.02% 328
2025
Q3 		$579K Buy
8,937
+394
+5% +$22.6K 0.02% 369
2025
Q2 		$416K Sell
8,543
-318
-4% -$12.3K 0.02% 378
2025
Q1 		$302K Buy
8,861
+2,840
+47% +$120K 0.01% 412
2024
Q4 		$237K Sell
6,021
-4,162
-41% -$197K 0.01% 460
2024
Q3 		$478K Sell
10,183
-5,477
-35% -$278K 0.02% 325
2024
Q2 		$846K Buy
15,660
+5,407
+53% +$313K 0.04% 245
2024
Q1 		$699K Buy
10,253
+5,784
+129% +$414K 0.04% 261
2023
Q4 		$280K Sell
4,469
-1,311
-23% -$72.5K 0.02% 345
2023
Q3 		$262K Buy
5,780
+735
+15% +$38K 0.02% 350
2023
Q2 		$283K Sell
5,045
-4,366
-46% -$248K 0.02% 331
2023
Q1 		$426K Buy
9,411
+2,730
+41% +$133K 0.03% 259
2022
Q4 		$272K Buy
6,681
+707
+12% +$37.5K 0.02% 322
2022
Q3 		$390K Sell
5,974
-1,315
-18% -$95.3K 0.03% 290
2022
Q2 		$443K Sell
7,289
-6,514
-47% -$383K 0.03% 269
2022
Q1 		$867K Buy
13,803
+2,056
+18% +$129K 0.05% 204
2021
Q4 		$890K Buy
11,747
+5,488
+88% +$479K 0.05% 187
2021
Q3 		$701K Buy
6,259
+2,543
+68% +$319K 0.05% 207
2021
Q2 		$602K Buy
3,716
+1,105
+42% +$134K 0.04% 243
2021
Q1 		$318K Buy
+2,611
New +$394K 0.03% 295

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SteelPeak Wealth's CRSP Position: Q2 2026 in Review

SteelPeak Wealth reduced its CRISPR Therapeutics (CRSP) stake by 69% in Q2 2026, selling an estimated $747K and leaving 6,314 shares worth $344K. The position accounts for 0.01% of the portfolio, ranked #497.

SteelPeak Wealth first reported a position in CRSP in Q1 2021 and has held it in 22 quarters since. The position peaked at $974K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SteelPeak Wealth held 6,314 shares of CRISPR Therapeutics worth $344K as of Q2 2026.
  • SteelPeak Wealth sold 14,165 CRISPR Therapeutics shares in Q2 2026, an estimated $747K.
  • CRISPR Therapeutics made up 0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #497 holding.
  • SteelPeak Wealth first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • SteelPeak Wealth's CRISPR Therapeutics position peaked at $974K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.